MacBride-Stewart Sean, Marwick Charis, Ryan Margaret, Guthrie Bruce
Pharmacy Services, NHS Greater Glasgow and Clyde, Glasgow.
Department of Population Health and Genomics, University of Dundee, Dundee.
Br J Gen Pract. 2022 Apr 29;72(722):e627-33. doi: 10.3399/BJGP.2021.0695.
Potentially inappropriate prescribing (PIP) of asthma bronchodilator inhalers is associated with increased morbidity and mortality.
To evaluate the effectiveness of feedback on the PIP of bronchodilator inhalers.
Pragmatic cluster randomised trial involving 235 of 244 (96.3%) GP practices in one Scottish health board.
Practices were randomly allocated (1:1 ratio) to individualised feedback (including visualised medication histories for each patient and action-oriented messages) on PIP of bronchodilator inhalers from prescription data; feedback reports were sent in July 2015, February 2016, and August 2016. Controls were sent feedback on an unrelated subject. The primary outcome was the change in the mean number of patients per practice with PIP of bronchodilator inhalers from the baseline period (August 2014-July 2015) until the post-feedback period (February 2016-January 2017), identified through a composite of five individual measures using prescription data.
In the analysis of the primary outcome, the mean number of patients with PIP of bronchodilator inhalers fell in the 118 practices that were sent feedback from 21.8 per practice to 17.7 per practice. Numbers fell marginally in the 115 control practices, from 20.5 per practice to 20.2 per practice, with a statistically significant difference between the two groups. There were 3.7 fewer patients per practice with PIP of bronchodilator inhalers in the intervention practices versus the control practices (95% confidence interval = -5.3 to -2.0).
Individualised feedback of PIP of asthma bronchodilators that included background information, visualised medication histories for each patient, and action-oriented messages was effective at reducing the number of patients exposed to excess or unsafe prescribing of bronchodilator inhalers.
哮喘支气管扩张剂吸入器的潜在不适当处方(PIP)与发病率和死亡率增加相关。
评估关于支气管扩张剂吸入器PIP的反馈的有效性。
一项实用的整群随机试验,涉及苏格兰一个卫生委员会244家全科医生诊所中的235家(96.3%)。
根据处方数据,将诊所按1:1比例随机分配,以获得关于支气管扩张剂吸入器PIP的个性化反馈(包括每位患者的可视化用药史和面向行动的信息);反馈报告于2015年7月、2016年2月和2016年8月发送。对照组收到关于一个不相关主题的反馈。主要结局是从基线期(2014年8月至2015年7月)到反馈后时期(2016年2月至2017年1月),每个诊所支气管扩张剂吸入器PIP患者的平均数量变化,通过使用处方数据的五项个体测量指标综合确定。
在主要结局分析中,收到反馈的118家诊所中,支气管扩张剂吸入器PIP患者的平均数量从每家诊所21.8例降至17.7例。115家对照诊所的数量略有下降,从每家诊所20.5例降至20.2例,两组间差异有统计学意义。干预组诊所中支气管扩张剂吸入器PIP患者每家诊所比对照组少3.7例(95%置信区间 = -5.3至 -2.0)。
哮喘支气管扩张剂PIP的个性化反馈,包括背景信息、每位患者的可视化用药史和面向行动的信息,在减少暴露于支气管扩张剂吸入器过量或不安全处方的患者数量方面是有效的。